A hypertonia a fejtett országokban az egyik leggyakoribb krónikus betegség és az egyik legfontosabb cardiovascularis kockázati tényező. A vérnyomás célértékre történő kezelésével jelentősen csökkenthető a coronariabetegség, a stroke, a krónikus vesebetegség kialakulásának a kockázata, illetve a mortalitás. A vérnyomáskontroll különösen a nagy kockázatú betegségekben játszik alapvető szerepet. A hypertonia kezelésében az életmódkezelésen kívül a gyógyszeres terápia játszik meghatározó szerepet. Az antihipertenzív terápia során is meghatározó jelentőségű a betegadherencia. A vérnyomáscsökkentő kezelés során a gyógyszer-perzisztencia csak mintegy 50%-os a kezelés első évére. A rezisztens hypertonia egyik fontos oka a nonadherencia. Az adherenciát befolyásoló tényezők között szerepet játszik a gyógyszerek száma, ezek napi adagolási gyakorisága, az alkalmazott gyógyszercsoportok tulajdonságai, az életkor és a nem is. Orv. Hetil., 2013, 154, 1587–1591.
Kiss, I.: Professional and organizational guideline for the treatment of hypertension in children and adults. [A hypertoniabetegség felnőttkori és gyermekkori kezelésének szakmai és szervezeti irányelvei.] Hypertonia és Nephrologia, 2009, 13 (Suppl. 2), 89–167. [Hungarian]
Kiss I. , 'Professional and organizational guideline for the treatment of hypertension in children and adults. [A hypertoniabetegség felnőttkori és gyermekkori kezelésének szakmai és szervezeti irányelvei.] ' (2009 ) 13 Hypertonia és Nephrologia : 89 -167 .
Marmot, M. G., Poulter, N. R.: Primary prevention of stroke. Lancet, 1992, 339, 344–347.
Poulter N. R. , 'Primary prevention of stroke ' (1992 ) 339 Lancet : 344 -347 .
Thompson, D. W., Furlan, A. J.: Clinical epidemiology of stroke. Neurol. Clin., 1996, 14, 309–315.
Furlan A. J. , 'Clinical epidemiology of stroke ' (1996 ) 14 Neurol. Clin. : 309 -315 .
Thaker, D., Frech, F., Suh, D., et al.: Prevalence of hypertension and ethnic differences in sociodemographic and cardiovascular health characteristics of US hypertensives. Am. J. Hypertens., 2005, 18 (Suppl. 1), A117.
Suh D. , 'Prevalence of hypertension and ethnic differences in sociodemographic and cardiovascular health characteristics of US hypertensives ' (2005 ) 18 Am. J. Hypertens. : A117 -.
Simonyi, G., Kollár, R.: Significance of patient adherence in cardiovascular therapy. [A beteg-együttműködés jelentősége a cardiovascularis terápiában.] Orv. Hetil., 2013, 154, 883–888. [Hungarian]
Kollár R. , 'Significance of patient adherence in cardiovascular therapy. [A beteg-együttműködés jelentősége a cardiovascularis terápiában.] ' (2013 ) 154 Orv. Hetil. : 883 -888 .
Van Wijk, B. L., Klungel, O. H., Heerdink, E. R., et al.: Rate and determinants of 10-year persistence with antihypertensive drugs. J. Hypertens., 2005, 23, 2101–2107.
Heerdink E. R. , 'Rate and determinants of 10-year persistence with antihypertensive drugs ' (2005 ) 23 J. Hypertens. : 2101 -2107 .
Psaty, B. M., Koepsell, T. D., Wagner, E. H., et al.: The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA, 1990, 263, 1653–1657.
Wagner E. H. , 'The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers ' (1990 ) 263 JAMA : 1653 -1657 .
Rangno, R. E., Langlois, S.: Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol. Am. Heart J., 1982, 104 (2 Pt 2), 473–478.
Langlois S. , 'Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol ' (1982 ) 104 Am. Heart J. : 473 -478 .
Johnson, B. F., Whelton, A.: A study design for comparing the effects of missing daily doses of antihypertensive drugs. Am. J. Ther., 1994, 1, 260–267.
Whelton A. , 'A study design for comparing the effects of missing daily doses of antihypertensive drugs ' (1994 ) 1 Am. J. Ther. : 260 -267 .
Leenen, F. H., Fourney, A., Notman, G., et al.: Persistence of anti-hypertensive effect after ‘missed doses’ of calcium antagonist with long (amlodipine) vs. short (diltiazem) elimination half-life. Br. J. Clin. Pharmacol., 1996, 41, 83–88.
Notman G. , 'Persistence of anti-hypertensive effect after ‘missed doses’ of calcium antagonist with long (amlodipine) vs. short (diltiazem) elimination half-life ' (1996 ) 41 Br. J. Clin. Pharmacol. : 83 -88 .
Deanfield, J. E., Detry, J. M., Sellier, P., et al.: Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial. J. Am. Coll. Cardiol., 2002, 40, 917–925.
Sellier P. , 'Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial ' (2002 ) 40 J. Am. Coll. Cardiol. : 917 -925 .
Tan, K. W., Leenen, F. H.: Persistence of anti-hypertensive effect after missed dose of perindopril. Br. J. Clin. Pharmacol., 1999, 48, 628–630.
Leenen F. H. , 'Persistence of anti-hypertensive effect after missed dose of perindopril ' (1999 ) 48 Br. J. Clin. Pharmacol. : 628 -630 .
Stephan, D., Grima, M., Welsch, M., et al.: Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system. Fundam. Clin. Pharmacol., 1996, 10, 474–483.
Welsch M. , 'Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system ' (1996 ) 10 Fundam. Clin. Pharmacol. : 474 -483 .
Leenen, F. H.: Intermittent blood pressure control: potential consequences for outcome. Can. J. Cardiol., 1999, 15 (Suppl. C), 13C–18C.
Leenen F. H. , 'Intermittent blood pressure control: potential consequences for outcome ' (1999 ) 15 Can. J. Cardiol. : 13C -18C .
Velasco, M., Soltero, I., Sukerman, M., et al.: Double-blind, randomized study of the efficacy, tolerance and rebound effects of the antihypertensive drug rilmenidine: comparative evaluation with clonidine. Cir. Ther. Res., 1993, 54, 202–207.
Sukerman M. , 'Double-blind, randomized study of the efficacy, tolerance and rebound effects of the antihypertensive drug rilmenidine: comparative evaluation with clonidine ' (1993 ) 54 Cir. Ther. Res. : 202 -207 .
Krousel-Wood, M., Thomas, S., Muntner, P., et al.: Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr. Opin. Cardiol., 2004, 19, 357–362.
Muntner P. , 'Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients ' (2004 ) 19 Curr. Opin. Cardiol. : 357 -362 .
Lip, G. Y., Beevers, D. G.: Doctors, nurses, pharmacists and patients – the Rational Evaluation and Choice in Hypertension (REACH) survey of hypertension care delivery. Blood Press. Suppl., 1997, 1, 6–10.
Beevers D. G. , 'Doctors, nurses, pharmacists and patients – the Rational Evaluation and Choice in Hypertension (REACH) survey of hypertension care delivery ' (1997 ) 1 Blood Press. Suppl. : 6 -10 .
Wallenius, S. H., Vainio, K. K., Korhonen, M. J., et al.: Self-initiated modification of hypertension treatment in response to perceived problems. Ann. Pharmacother., 1995, 29, 1213–1217.
Korhonen M. J. , 'Self-initiated modification of hypertension treatment in response to perceived problems ' (1995 ) 29 Ann. Pharmacother. : 1213 -1217 .
Benson, J., Britten, N.: Patients’ views about taking antihypertensive drugs: questionnaire study. BMJ, 2003, 326, 1314–1315.
Britten N. , 'Patients’ views about taking antihypertensive drugs: questionnaire study ' (2003 ) 326 BMJ : 1314 -1315 .
Bakris, G. L., Williams, M., Dworkin, L., et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis., 2000, 36, 646–661.
Dworkin L. , 'Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group ' (2000 ) 36 Am. J. Kidney Dis. : 646 -661 .
Williams, B.: Drug treatment of hypertension. Most patients will need a treatment cocktail-including a thiazide diuretic. BMJ, 2003, 326, 61–62.
Williams B. , 'Drug treatment of hypertension. Most patients will need a treatment cocktail-including a thiazide diuretic ' (2003 ) 326 BMJ : 61 -62 .
Dezii, C. M.: A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag. Care, 2000, 9 (Suppl.), 2–6.
Dezii C. M. , 'A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension ' (2000 ) 9 Manag. Care : 2 -6 .
Claxton, A. J., Cramer, J., Pierce, C.: A systematic review of the associations between dose regimens and medication compliance. Clin. Ther., 2001, 23, 1296–1310.
Pierce C. , 'A systematic review of the associations between dose regimens and medication compliance ' (2001 ) 23 Clin. Ther. : 1296 -1310 .
Monane, M., Bohn, R. L., Gurwitz, J. H., et al.: Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am. J. Public Health, 1996, 86, 1805–1808.
Gurwitz J. H. , 'Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race ' (1996 ) 86 Am. J. Public Health : 1805 -1808 .
Monane, M., Bohn, R. L., Gurwitz, J. H., et al.: The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am. J. Hypertens., 1997, 10, 697–704.
Gurwitz J. H. , 'The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly ' (1997 ) 10 Am. J. Hypertens. : 697 -704 .
Rizzo, J. A., Simons, W. R.: Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin. Ther., 1997, 19, 1446–1457.
Simons W. R. , 'Variations in compliance among hypertensive patients by drug class: implications for health care costs ' (1997 ) 19 Clin. Ther. : 1446 -1457 .
Borzecki, A. M., Glickman, M. E., Kader, B., et al.: The effect of age on hypertension control and management. Am. J. Hypertens., 2006, 19, 520–527.
Kader B. , 'The effect of age on hypertension control and management ' (2006 ) 19 Am. J. Hypertens. : 520 -527 .
Ghali, J. K., Kadakia, S., Copper, R., et al.: Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch. Intern. Med., 1988, 148, 2013–2016.
Copper R. , 'Precipitating factors leading to decompensation of heart failure. Traits among urban blacks ' (1988 ) 148 Arch. Intern. Med. : 2013 -2016 .
Van Wijk, B. L., Klungel, O. H., Heerdink, E. R., et al.: The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J. Hypertens., 2004, 22, 1831–1837.
Heerdink E. R. , 'The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen ' (2004 ) 22 J. Hypertens. : 1831 -1837 .
Fischer, M. A., Avorn, J.: Economic implications of evidence-based prescribing for hypertension: Can better care cost less? JAMA, 2004, 291, 1850–1856.
Avorn J. , 'Economic implications of evidence-based prescribing for hypertension: Can better care cost less? ' (2004 ) 291 JAMA : 1850 -1856 .
Kaplan, N. M.: Resistant hypertension. J. Hypertens., 2005, 23, 1441–1444.
Kaplan N. M. , 'Resistant hypertension ' (2005 ) 23 J. Hypertens. : 1441 -1444 .
Egan, B. M., Zhao, Y., Axon, R. N., et al.: Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation, 2011, 124, 1046–1058.
Axon R. N. , 'Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008 ' (2011 ) 124 Circulation : 1046 -1058 .
Burnier, M., Schneider, M. P., Chioléro, A., et al.: Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J. Hypertens., 2001, 19, 335–341.
Chioléro A. , 'Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions ' (2001 ) 19 J. Hypertens. : 335 -341 .
Jung, O., Gechter, J. L., Wunder, C., et al.: Resistant hypertension? Assessment of adherence by toxicological urine analysis. J. Hypertens., 2013, 31, 766–774.
Wunder C. , 'Resistant hypertension? Assessment of adherence by toxicological urine analysis ' (2013 ) 31 J. Hypertens. : 766 -774 .
Kronish, I. M., Woodward, M., Sergie, Z., et al.: Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation, 2011, 123, 1611–1621.
Sergie Z. , 'Meta-analysis: impact of drug class on adherence to antihypertensives ' (2011 ) 123 Circulation : 1611 -1621 .